Effects of whole-grain wheat, rye, and lignan supplementation on cardiometabolic risk factors in men with metabolic syndrome: A randomized crossover trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • Anne K. Eriksen, Sveriges Lantbruksuniversitet, Danish Cancer Society
  • ,
  • Carl Brunius, Chalmers University of Technology
  • ,
  • Mohsen Mazidi, Chalmers University of Technology
  • ,
  • Per M. Hellström, Uppsala University
  • ,
  • Ulf Risérus, Uppsala University
  • ,
  • Kia N. Iversen, Chalmers University of Technology
  • ,
  • Rikard Fristedt, Chalmers University of Technology
  • ,
  • Li Sun, Sveriges Lantbruksuniversitet
  • ,
  • Yi Huang, Sveriges Lantbruksuniversitet, Guangxi University
  • ,
  • Natalja P. Nørskov
  • Knud Erik B. Knudsen
  • Cecilie Kyrø, Danish Cancer Society
  • ,
  • Anja Olsen
  • Anne Tjønneland, Danish Cancer Society
  • ,
  • Johan Dicksved, Sveriges Lantbruksuniversitet
  • ,
  • Rikard Landberg, Chalmers University of Technology

A whole-grain (WG)-rich diet has shown to have potential for both prevention and treatment of the metabolic syndrome (MetS), which is a cluster of risk factors that increase the risk of type 2 diabetes and cardiovascular disease. Different WGs may have different health effects. WG rye, in particular, may improve glucose homeostasis and blood lipids, possibly mediated through fermentable dietary fiber and lignans. Recent studies have also suggested a crucial role of the gut microbiota in response to WG. Objectives: The aim was to investigate WG rye, alone and with lignan supplements [secoisolariciresinol diglucoside (SDG)], and WG wheat diets on glucose tolerance [oral-glucose-tolerance test (OGTT)], other cardiometabolic outcomes, enterolignans, and microbiota composition. Moreover, we exploratively evaluated the role of gut microbiota enterotypes in response to intervention diets. Methods: Forty men with MetS risk profile were randomly assigned to WG diets in an 8-wk crossover study. The rye diet was supplemented with 280 mg SDG at weeks 4-8. Effects of treatment were evaluated by mixed-effects modeling, and effects on microbiota composition and the role of gut microbiota as a predictor of response to treatment were analyzed by random forest plots. Results: The WG rye diet (± SDG supplements) did not affect the OGTT compared with WG wheat. Total and LDL cholesterol were lowered (-0.06 and -0.09 mmol/L, respectively; P < 0.05) after WG rye compared with WG wheat after 4 wk but not after 8 wk. WG rye resulted in higher abundance of Bifidobacterium [fold-change (FC) = 2.58, P < 0.001] compared with baseline and lower abundance of Clostridium genus compared with WG wheat (FC = 0.54, P = 0.02). The explorative analyses suggest that baseline enterotype is associated with total and LDL-cholesterol response to diet. Conclusions: WG rye, alone or with SDG supplementation, compared with WG wheat did not affect glucose metabolism but caused transient LDL-cholesterol reduction. The effect of WG diets appeared to differ according to enterotype. This trial was registered at www.clinicaltrials.gov as NCT02987595.

Original languageEnglish
JournalAmerican Journal of Clinical Nutrition
Pages (from-to)864-876
Number of pages13
Publication statusPublished - Apr 2020

    Research areas

  • cardiometabolic, enterotype, glucose-tolerance test, lignan, lipid profile, rye, wheat, whole grain

See relations at Aarhus University Citationformats

ID: 187085393